TY - JOUR
T1 - Health economic impact of liquid biopsies in cancer management
AU - IJzerman, Maarten J.
AU - Berghuis, A. M.Sofie
AU - de Bono, Johann S.
AU - Terstappen, Leon W.M.M.
N1 - Funding Information:
This work was supported in part by the EU FP7 HEALTH.2012.1.2-1 program 305341 CTCTrap. In addition, the de Bono laboratory was funded by an EU-FP7 grant (CTC-TRAP), an Experimental Cancer Medicine Centre grant and a Cancer Research UK Centre grant as well as a November Prostate Cancer Centre of Excellence grant.
Publisher Copyright:
© 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2018/11/2
Y1 - 2018/11/2
N2 - Introduction: Liquid biopsies (LBs) are referred to as the sampling and analysis of non-solid tissue, primarily blood, as a diagnostic and monitoring tool for cancer. Because LBs are largely non-invasive, they are a less-costly alternative for serial analysis of tumor progression and heterogeneity to facilitate clinical management. Although a variety of tumor markers are proposed (e.g., free-circulating DNA), the clinical evidence for Circulating Tumor Cells (CTCs) is currently the most developed. Areas covered: This paper presents a health economic perspective of LBs in cancer management. We first briefly introduce the requirements in biomarker development and validation, illustrated for CTCs. Second, we discuss the state-of-art on the clinical utility of LBs in breast cancer in more detail. We conclude with a future perspective on the clinical use and reimbursement of LBs Expert commentary: A significant increase in clinical research on LBs can be observed and the results suggest a rapid change of cancer management. In addition to studies evaluating clinical utility of LBs, a smooth translation into clinical practice requires systematic assessment of the health economic benefits. This paper argues that (early stage) health economic research is required to facilitate its clinical use and to prioritize further evidence development.
AB - Introduction: Liquid biopsies (LBs) are referred to as the sampling and analysis of non-solid tissue, primarily blood, as a diagnostic and monitoring tool for cancer. Because LBs are largely non-invasive, they are a less-costly alternative for serial analysis of tumor progression and heterogeneity to facilitate clinical management. Although a variety of tumor markers are proposed (e.g., free-circulating DNA), the clinical evidence for Circulating Tumor Cells (CTCs) is currently the most developed. Areas covered: This paper presents a health economic perspective of LBs in cancer management. We first briefly introduce the requirements in biomarker development and validation, illustrated for CTCs. Second, we discuss the state-of-art on the clinical utility of LBs in breast cancer in more detail. We conclude with a future perspective on the clinical use and reimbursement of LBs Expert commentary: A significant increase in clinical research on LBs can be observed and the results suggest a rapid change of cancer management. In addition to studies evaluating clinical utility of LBs, a smooth translation into clinical practice requires systematic assessment of the health economic benefits. This paper argues that (early stage) health economic research is required to facilitate its clinical use and to prioritize further evidence development.
KW - biomarker
KW - cancer
KW - circulating tumor cells
KW - ctDNA
KW - diagnostic
KW - health economics
KW - Liquid biopsies
UR - http://www.scopus.com/inward/record.url?scp=85052058363&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/30052095
U2 - 10.1080/14737167.2018.1505505
DO - 10.1080/14737167.2018.1505505
M3 - Article
C2 - 30052095
AN - SCOPUS:85052058363
SN - 1473-7167
VL - 18
SP - 593
EP - 599
JO - Expert Review of Pharmacoeconomics and Outcomes Research
JF - Expert Review of Pharmacoeconomics and Outcomes Research
IS - 6
ER -